Pyxis Oncology GAAP EPS of -$0.35 in-line

* Pyxis Oncology press release [https://seekingalpha.com/pr/20289283-pyxis-oncology-provides-business-update-and-reports-third-quarter-2025-financial-results] (PYXS [https://seekingalpha.com/symbol/PYXS]): Q3 GAAP EPS of -$0.35 in-line.
* As of September 30, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $77.7 million. The Company believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.

MORE ON PYXIS ONCOLOGY

* Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) [https://seekingalpha.com/article/4822516-pyxis-oncology-readouts-ahead-although-cash-might-dwindle-rating-downgrade]
* Seeking Alpha’s Quant Rating on Pyxis Oncology [https://seekingalpha.com/symbol/PYXS/ratings/quant-ratings]
* Historical earnings data for Pyxis Oncology [https://seekingalpha.com/symbol/PYXS/earnings]
* Financial information for Pyxis Oncology [https://seekingalpha.com/symbol/PYXS/income-statement]